Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study

Messa, Emanuela; Gioia, Daniela; Masiera, Elisa; Castiglione, Anna; Ceccarelli, Manuela; Salvi, Flavia; Danise, Paolo; Sanna, Alessandro; Allione, Bernardino; Balleari, Enrico; Poloni, Antonella; Cametti, Gianni; Ferrero, Dario; Tassara, Rodolfo; Finelli, Carlo; Bonferroni, Margherita; Musto, Pellegrino; Saglio, Giuseppe; Levis, Alessandro

doi:10.3324/haematol.2017.183590

Cited by 11 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, hemoglobin level pre-treatment in our cohort was 7.3-8.9 g/dL. We demonstrated overall survival benefit in patients who responded to ESAs which is concordant with the results of Messa et al, (2019) who reported an improvement in survival of patients with erythroid response with hemoglobin 8-10 g/dL pre-treatment. Limitations of this study are the small number of patients and the unavailability of DNA for target sequencing in all patients.…”

Section: Discussionsupporting

confidence: 90%

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes

Hattakitpanitchakul

Kobbuaklee

Wudhikarn

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

The natural history and prognosis of MDS are classified by the International Prognostic Scoring System (IPSS) and Revised International Prognostic Scoring System (R-IPSS). In low-risk MDS (low or intermediate-1 IPSS or R-IPSS ≤ 3.5), anemia is the predominant feature, often leading to red blood cell (RBC) transfusion requirement, poor quality of life, and worsening cardiovascular comorbidities (Steensma and Bennett, 2006). Correcting anemia by transfusion support or enhancing intrinsic

show abstract

Section: Discussionsupporting

confidence: 90%

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes

Hattakitpanitchakul

Kobbuaklee

Wudhikarn

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…In an analysis of data from a Canadian MDS registry, Buckstein et al 28 showed that transfusion dependence was associated with a poor prognosis, and that even intermittent achievement of RBC-TI was associated with improved OS. Messa et al 34 published results from the Italian Foundation of Myelodysplastic Syndromes (FISM) registry consistent with these results, e880 Clinical Lymphoma, Myeloma and Leukemia September 2022 although they were limited to ESA-treated patients with MDS with a specific range of Hb values.…”

Section: Valeria Santini Et Almentioning

confidence: 78%

“…26 , 27 Some studies have shown that achievement of RBC-TI with ESA treatment affects OS positively and reduces the risk of AML progression in the short term. [28][29][30][31][32][33][34] However, the longer-term impact of RBC-TI achievement on OS is not yet known, and the incremental effect of TB on OS has not been well-studied. 28 Assessing survival outcomes in LR-MDS remains a challenge.…”

Section: Valeria Santini Et Almentioning

confidence: 99%

Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes

Giagounidis¹,

Pelligra²,

Franco‐Villalobos³

et al. 2022

Clinical Lymphoma Myeloma and Leukemia

Self Cite

View full text Add to dashboard Cite

“…Even in this subgroup only the minority patients (approximately 1/3) show improvement in erythropoiesis, and with no overall survival benefit. 30 RBC transfusions are generally reserved for patients with symptomatic anaemia with a haemoglobin of <80–100 g/L (8–10 g/dL). 18 …”

Section: Resultsmentioning

confidence: 99%

Practice review: Evidence-based and effective management of anaemia in palliative care patients

et al. 2022

View full text Add to dashboard Cite

Background: Anaemia is a common sequela of advanced disease and is associated with significant symptom burden. No specific guidance exists for the investigation and management of anaemia in palliative care patients. Aim: We aim to offer a pragmatic overview of the approaches to investigate and manage anaemia in advanced disease, based on guidelines and evidence in disease specific patient groups, including cancer, heart failure and chronic kidney disease. Design: Scoping review methodology was used to determine the strength of evidence supporting the investigation and management of anaemia in patients with advanced disease. Data sources: A search for guidelines was performed in 2020. National or international guidelines were examined if they described the investigation or management of anaemia in adult patients with health conditions seen by palliative care services written within the last 5 years in the English language. Searches of MEDLINE, the Cochrane library and WHO guidance were made in 2019 to identify key publications that provided additional primary data. Results: Evidence supports patient-centred investigation of anaemia, results of which should guide targeted intervention. Blanket use of blood transfusion should be avoided, with evidence supporting a more restrictive approach to transfusion. Routine use of oral iron and erythropoetin stimulating agents (ESAs) are not recommended. Insufficient evidence exists to determine the effectiveness of IV iron in this patient group. Conclusion: We advocate early consideration and investigation of anaemia, guided by symptom burden and patient preferences. Correction of reversible causes should be the mainstay of treatment, with a restrictive approach to blood transfusion. Research is required to evaluate the efficacy of IV iron in these patients.

show abstract

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study

Cited by 11 publications

References 15 publications

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes

Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes

Practice review: Evidence-based and effective management of anaemia in palliative care patients

Contact Info

Product

Resources

About